Literature DB >> 32082773

Experience in totally implantable venous port catheter: Analysis of 3,000 patients in 12 years.

Fazlı Yanık1, Yekta Altemur Karamustafaoğlu1, Adem Karataş1, Yener Yörük1.   

Abstract

BACKGROUND: This study aims to present our experience with patients who were performed totally implantable venous port catheter.
METHODS: Demographics-clinical features, surgical results and complications of 3,000 patients (1,824 males, 1,176 females; mean age 61.04±11.5 years; range, 18 to 88 years) who were performed totally implantable venous port catheter between March 2005 and March 2017 were evaluated retrospectively. Totally implantable venous port catheter indications, complications, catheter duration of stay, reasons for catheter removal and statistical analysis information were reported in detail by reviewing patient records.
RESULTS: Of the cases, the Seldinger method was used in 98%, 1% (n=36) had the catheter inserted with superficial Doppler ultrasonography, while the veins were not found in 1% (n=29) and these patients were excluded from the study. Totally implantable venous port catheter was inserted via right internal jugular vein in 2,095 patients (70%), via right subclavian vein in 470 patients (16%), via left internal jugular vein in 290 patients (10%), and via left subclavian vein in 106 patients (3%). Mean duration of stay for totally implantable venous port catheter was 46.7 months (range, 1 to 78 months). Complications were detected in a total of 288 patients (9.6%), 153 (5.1%) being early and 135 (4.5%) being late. The most common oncologic indication was colorectal cancer. The rate of port removal was 298/3,000 (9.9%) and the main reasons were infection, thrombosis, pain, and end of treatment. Totally implantable venous port catheter was required to be inserted twice in 33 patients (1%) and thrice in 14 patients (0.5%). Totally implantable venous port catheter had malposition in eight patients and all were revised successfully with over the guide method.
CONCLUSION: Totally implantable venous port catheter may increase the quality of life in cancer patients. Despite possible complications, totally implantable venous port catheter is safe and comfortable for long-term intravenous treatment. Possible complications may be prevented or managed when totally implantable venous port catheter is performed by surgeons with adequate experience.
Copyright © 2018, Turkish Society of Cardiovascular Surgery.

Entities:  

Keywords:  Catheter; central vein; implantable; port

Year:  2018        PMID: 32082773      PMCID: PMC7018272          DOI: 10.5606/tgkdc.dergisi.2018.15299

Source DB:  PubMed          Journal:  Turk Gogus Kalp Damar Cerrahisi Derg        ISSN: 1301-5680            Impact factor:   0.332


  16 in total

1.  [Intensive care nurses' knowledge about the evidence-based guidelines of preventing central venous catheter related infection].

Authors:  Akos Csomós; Ede Orbán; Rózsa Konczné Réti; Erika Vass; Katalin Darvas
Journal:  Orv Hetil       Date:  2008-05-18       Impact factor: 0.540

Review 2.  Totally Implantable Venous Access Devices: A Review of Complications and Management Strategies.

Authors:  Omidreza Tabatabaie; Gyulnara G Kasumova; Mariam F Eskander; Jonathan F Critchlow; Nicholas E Tawa; Jennifer F Tseng
Journal:  Am J Clin Oncol       Date:  2017-02       Impact factor: 2.339

3.  Trapezius placement of implanted ports: understanding the procedure.

Authors:  Steve Hill
Journal:  Br J Nurs       Date:  2016 Jan 28-Feb 10

4.  Totally implantable venous access port via the femoral vein in a femoral port position with CT-venography.

Authors:  Kazuya Kato; Yoshiaki Iwasaki; Kazuhiko Onodera; Mineko Higuchi; Kimitaka Kato; Yurina Kato; Minoru Matsuda; Seiya Endo; Yuko Kobashi; Masahiko Taniguchi
Journal:  J Surg Oncol       Date:  2016-09-22       Impact factor: 3.454

5.  Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients.

Authors:  A Kakkos; L Bresson; D Hudry; S Cousin; C Lervat; E Bogart; J P Meurant; S El Bedoui; G Decanter; K Hannebicque; C Regis; A Hamdani; N Penel; E Tresch-Bruneel; F Narducci
Journal:  Eur J Surg Oncol       Date:  2016-11-05       Impact factor: 4.424

6.  Clinical review and analysis of complications of totally implantable venous access devices for chemotherapy.

Authors:  Jung Tae Kim; Tae Yun Oh; Woon Ha Chang; Young Kyun Jeong
Journal:  Med Oncol       Date:  2011-03-06       Impact factor: 3.064

Review 7.  Port-A-Cath infections in children with cancer.

Authors:  H Hengartner; C Berger; D Nadal; F K Niggli; M A Grotzer
Journal:  Eur J Cancer       Date:  2004-11       Impact factor: 9.162

8.  [Brachial fluoroscopically guided implantation of venous port devices in oncology patients].

Authors:  Pierre-Yves Marcy; Nicolas Magné; Cédric Bailet; Jean-Claude Gallard; Bruno Valenza; Maurice Schneider; François Demard; Franck Bentolila
Journal:  Bull Cancer       Date:  2002 Jul-Aug       Impact factor: 1.276

Review 9.  Routine Antibiotic Prophylaxis for Totally Implantable Venous Access Device Placement: Meta-Analysis of 2,154 Patients.

Authors:  Evan Johnson; James Babb; Divya Sridhar
Journal:  J Vasc Interv Radiol       Date:  2016-01-06       Impact factor: 3.464

Review 10.  Clinical outcome after a totally implantable venous access port-related infection in cancer patients: a prospective study and review of the literature.

Authors:  David Lebeaux; Béatrice Larroque; Justine Gellen-Dautremer; Véronique Leflon-Guibout; Chantal Dreyer; Suzanne Bialek; Antoine Froissart; Olivia Hentic; Catherine Tessier; Raymond Ruimy; Anne-Laure Pelletier; Bruno Crestani; Michel Fournier; Thomas Papo; Béatrix Barry; Virginie Zarrouk; Bruno Fantin
Journal:  Medicine (Baltimore)       Date:  2012-11       Impact factor: 1.889

View more
  1 in total

1.  Long-Term Results of a Standard Algorithm for Intravenous Port Implantation.

Authors:  Ching-Feng Wu; Jui-Ying Fu; Chi-Tsung Wen; Chien-Hung Chiu; Ming-Ju Hsieh; Yun-Hen Liu; Hui-Ping Liu; Ching-Yang Wu
Journal:  J Pers Med       Date:  2021-04-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.